Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05444049 · ClinicalTrials.gov registry record · NA

NEURESCUE Device as an Adjunct to In-Hospital Cardiac Arrest (ARISE)

A NA study of Cardiovascular Diseases and Cardiac Arrest, sponsored by neurescue.

Completed
Registry status
NA
Development phase
6
Enrollment target
1
Study location

NCT05444049 is a NA study of Cardiovascular Diseases and Cardiac Arrest that has completed, run by neurescue. The registered enrollment target is 6 participants, below the 26,974-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05444049, a NA study of Cardiovascular Diseases and Cardiac Arrest, has completed, sponsored by neurescue.

COMPLETED
Registry status
NA
Development phase
6 participants
Enrollment target
1
Study location

Study Summary

The NEURESCUE device is the first intelligent catheter for aortic balloon occlusion, an emergency technique that supercharges blood flow to the heart and brain within one minute from deployment. The catheter-based device is delivered via the femoral artery, temporarily inflating a soft balloon in the descending aorta to redirect blood flow towards the upper body. The objective of this study is to investigate the feasibility of the NEURESCUE device as an adjunct to Advanced Cardiac Life Support (ACLS) in adults with cardiac arrest.

Interventions

  • DEVICE NEURESCUE device

Study Locations (1)

California

  • Long Beach Medical Center - Long Beach

Trial Details

FieldValue
Enrollment Target 6 participants
Start Date 2022-12-08
Est. Completion 2024-09-30
Phase NA

Sponsor

neurescue

1 total trials

What the Registry Record Tells You About NCT05444049

The ClinicalTrials.gov registry entry for NCT05444049 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 26,974-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (100% lower). The listed sponsor is neurescue, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Cardiovascular Diseases appearing as the primary indexed condition, and to 1 intervention - of which NEURESCUE device is the first listed.

NCT05444049 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT05444049 about?

NCT05444049 is a clinical study titled "NEURESCUE Device as an Adjunct to In-Hospital Cardiac Arrest (ARISE)". The NEURESCUE device is the first intelligent catheter for aortic balloon occlusion, an emergency technique that supercharges blood flow to the heart and brain within one minute from deployment. The catheter-based device is delivered via the femoral artery, temporarily inflating a soft balloon in t...

What is the current status of trial NCT05444049?

This trial is currently completed. It is a NA study. The enrollment target is 6 participants. The study started on 2022-12-08. Estimated completion is 2024-09-30.

What conditions does trial NCT05444049 study?

This clinical trial studies the following conditions: Cardiovascular Diseases, Cardiac Arrest, Cardiopulmonary Arrest.

What interventions are being tested in trial NCT05444049?

The interventions under investigation include: NEURESCUE device (DEVICE).

Who is sponsoring clinical trial NCT05444049?

This trial is sponsored by neurescue, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05444049 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cardiovascular Diseases

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.